PRESERFLO® MicroShunt Extension Study

CompletedOBSERVATIONAL
Enrollment

279

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

November 24, 2022

Study Completion Date

November 24, 2022

Conditions
Primary Open-angle Glaucoma
Interventions
DEVICE

PRESERFLO® MicroShunt

Device surgically implanted

PROCEDURE

Trabeculectomy

The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.

Trial Locations (23)

10003

New York Eye and Ear Infirmary of Mt. Sinai, New York

12159

Glaucoma Consultants of the Capital Region, Slingerlands

19004

Ophthalmic Partners of Pennsylvania, Bala-Cynwyd

28040

Hospital Clínico San Carlos, Madrid

33600

Pôle Ophtalmologique de la Clinique Mutualiste, Pessac

43215

Ophthalmic Surgeons and Consultants of Ohio, Columbus

45242

Cincinnati Eye Institute, Cincinnati

46290

Eugene and Marilyn Glick Eye Institute, Indianapolis

55431

Minnesota Eye Consultants, PA, Bloomington

56124

A. O.U.P (Azienda Ospedaliere Universitaria Pisana) Stabilimento di Cisanello, Pisa

66213

Stiles Eye Care Excellence & Glaucoma Institute, Overland Park

72704

Vold Vision, Fayetteville

73014

Dean McGee Eye Institute, Oklahoma City

75231

Glaucoma Associates of Texas, Dallas

76102

Ophthalmology Associates, Fort Worth

77030

University Eye Associates, Houston

78229

R&R Eye Research, LLC, San Antonio

83616

Intermountain Eye Center, Eagle

85306

Arizona Advance Eye Research Institute, LLC., Glendale

90095

UCLA Medical Center Jules Stein Eye Institute, Los Angeles

95817

University of California at Davis Eye Center, Sacramento

06450

Ophthalmic Consultants of Connecticut, Meriden

EC1V 2PD

Moorfields Eye Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

InnFocus Inc.

INDUSTRY